Abstract: Disclosed herein is a long acting pharmaceutical composition for treating or preventing human immunodeficiency virus (HIV) infection. The pharmaceutical composition comprises a suspension of a lysine-based aspartyl protease inhibitor or salt thereof, a surface modifier, and a pharmaceutically acceptable carrier; wherein the lysine-based aspartyl protease inhibitor or salt thereof has an average effective particle size of less than about 500 nm. A method for treating or preventing HIV infection with the pharmaceutical composition is also disclosed.

Abstract: A method for preparing a polyarylene sulfide includes reacting a methyl 4-(arylthio)aryl sulfoxide compound with sulfuric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid or trifluoromethanesulfonic acid to obtain a polysulfonium intermediate; and demethylating the polysulfonium intermediate to obtain a polyarylene sulfide, wherein the polysulfonium intermediate is demethylated with aqueous HCl, HBr, or HI.

Abstract: A method for preparing an aromatic sulfide or a salt thereof is provided. The method for preparing an aromatic sulfide or a salt thereof includes reacting a compound having a structure represented by Formula (I) to a compound having a structure represented by Formula (III) in the presence of a compound having a structure represented by Formula (II) to obtain a compound having a structure represented by Formula (IV) wherein R1 and R2 are independently C1-6 alkyl group, or C5-7 cycloalkyl group; R3 is independently C1-6 alkyl group, C5-7 cycloalkyl group, C1-6 haloalkyl group, or aryl group; R4 is independently H, or C1-6 alkyl group; Y is H, aryl group, or —X—R5; X is —O—, —NH—, —PH—, or —S—, or Y and an adjacent R4 are optionally combined with the carbon atoms to which they are attached, to form an aryl group; and R5 is H, C1-6 alkyl group, C5-7 cycloalkyl group, or aryl group; and Z? is R3SO3?.

Abstract: A method for preparing a cationic sulfoxide intermediate having the following formula wherein Ar1 and Ar2 are substituted or unsubstituted aryl groups that are the same or different, includes reacting hydrogen peroxide with (i) a compound having the following formula (2) or sulfonic acid R?SO3H, wherein R? is CH3, CF3, phenyl, toluene, or OH, and (ii) a cationic thioether intermediate having the following formula (4) to obtain the cationic sulfoxide intermediate: wherein R is a substituted or unsubstituted C1-C6 alkyl group; and wherein Ar1 and Ar2 are as defined above and Y is an anion.

Abstract: A polymer is provided. The polymer has a repeating unit having a structure represented by Formula (I) or Formula (II) wherein Ar1 and Ar2 can be substituted or unsubstituted aryl diradical; Y? can be R2SO3? or ClO4?; R1 can be C1-6 alkyl; Ar1 and Ar2 are different; and, R2 can be C1-6 alkyl, substituted or unsubstituted aromatic ring, or C1-6 haloalkyl.

Abstract: A method for preparing a polymer is provided. The method for preparing a polymer includes subjecting at least one monomer having a structure represented by Formula (I) to a reaction in the presence of sulfonic acid, diphenyl amine, and oxygen-containing phosphide, obtaining a sulfonium salt polymer wherein x is 0, 1, or 2, R1 is C1-6 alkyl group; and R2 is independently hydrogen, or C1-6 alkyl group.

Abstract: A dianhydride and a polyimide formed by the same are provided. The dianhydride has a chemical structure represented below: wherein Ar is a fluorene-containing group. The dianhydride can be polymerized with a diamine to form a polyimide with a repeating unit of a chemical formula: wherein Ar is the fluorene-containing group, and n is a positive integer from 1 to 5. The polyimide simultaneously has excellent thermal stability and hot workability, and can therefore be applied in several industries.

Abstract: A dianhydride and a polyimide formed by the same are provided. The dianhydride has a chemical structure represented below: wherein Ar is a fluorene-containing group. The dianhydride can be polymerized with a diamine to form a polyimide with a repeating unit of a chemical formula: wherein Ar is the fluorene-containing group, and n is a positive integer from 1 to 5. The polyimide simultaneously has excellent thermal stability and hot workability, and can therefore be applied in several industries.

Abstract: A polyester film is provided. The polyester film is produced from a composition that includes the following monomers: terephthalic acid, ethylene glycol, and a branched monomer having a structure represented by formula (I), formula (II) or formula (III): , wherein X is independently hydroxyl, carboxyl or —COOR, and R is C1-6 alkyl. The molar ratio between terephthalic acid and ethylene glycol ranges is between about 50:50 and 30:70. The molar percentage of the branched monomer is from about 1 mol % to 3 mol %, based on the total mole of terephthalic acid and ethylene glycol.

Abstract: The disclosure provides a polyester composition and a polyester article. According to an embodiment, the polyester composition includes a polyester and a branched monomer. The branched monomer has a structure represented by formula (I) or formula (II): wherein R is independently hydrogen, fluorine, chlorine, bromine, or C1-6 alkyl.

Abstract: The disclosure provides a polyester composition and a polyester article. According to an embodiment, the polyester composition includes a polyester and a branched monomer. The branched monomer has a structure represented by formula (I) or formula (H): wherein R is independently hydrogen, fluorine, chlorine, bromine, or C1-6 alkyl.

Abstract: Compounds represented by the formula (I) or pharmaceutically acceptable salts thereof: R2—Y—Z-Q-A-R1??Formula (I) wherein R1, R2, Y, Z, Q, and A are as defined. These compounds are inhibitors of tubulin polymerization by binding at colchicines binding site and are useful in the treatment of tumors or mitotic diseases such as cancers, gout, and other conditions associated with abnormal cell proliferation.

Abstract: The disclosure provides a masterbatch, a method for fabricating the same and a film formed from the masterbatch. The masterbatch includes a product prepared from a composition via polymerization and granulation. The composition includes: terephthalic acid; and a silicon dioxide dispersion, wherein the silicon dioxide dispersion includes surface-modified silicon dioxide particles disposed within ethylene glycol, and the surface-modified silicon dioxide particle has first functional groups and second functional groups bonded on the surface of the silicon dioxide particles, wherein the first functional groups have a structure represented by and the second functional groups include a C1-8 haloalkyl functional group, C1-8 alkoxy functional group, C1-8 aminoalkyl functional group, C2-8 alkenyl group, or epoxy group, R1 is hydrogen or a C1-3 alkyl functional group, and n is 1-4.

Abstract: The disclosure provides a catalyst composition, including: a metal or metal compound; and an organic diacid metal salt. The metal includes titanium (Ti), stibium (Sb) or combinations thereof and the metal compound includes antimony oxide (Sb2O3) or tetra-n-butoxy titanium (TBT). The catalyst composition includes about 0.3-6 wt % of the metal or metal compound and about 94-99.7 wt % of the organic diacid metal salt.

Abstract: Compounds represented by the formula (I) or pharmaceutically acceptable salts thereof: R2—Y—Z-Q-A-R1??Formula (I) wherein R1, R2, Y, Z, Q, and A are as defined. These compounds are inhibitors of tubulin polymerization by binding at colchicines binding site and are useful in the treatment of tumors or mitotic diseases such as cancers, gout, and other conditions associated with abnormal cell proliferation.

Abstract: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

Abstract: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

Abstract: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (A) are inhibitors N of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

Abstract: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

Abstract: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.